Key Highlights

  • Burning Rock Biotech reported second quarter Revenue of 134.8 million yuan, down 9.3 percent year over year but up sequentially from the first quarter.
  • Net loss widened to 18.4 million yuan from 9.7 million yuan in the same period last year.
  • In-hospital Business revenue grew 7.4 percent year over year to 67.1 million yuan, while pharma Research and Development revenue declined 31.8 percent.
  • Several diagnostic products entered priority or special review channels with China's National Medical Products Administration during the quarter.

A Sequential Recovery Following a Challenging Start to the Year

Burning Rock Biotech Limited (NASDAQ:BNR), a China based precision oncology company focused on next generation sequencing diagnostics, reported second quarter revenue of 134.8 million yuan, down 9.3 percent from the prior year period but representing a sequential improvement from the 107.9 million yuan reported in the first quarter. Chairman and Chief Executive Officer Yusheng Han characterized the results as the anticipated recovery following a volatile first quarter.

Performance varied notably across the company's three business channels. In-hospital business revenue, which reflects the company's strategic shift toward embedding diagnostic laboratories directly within partner hospitals, grew 7.4 percent to 67.1 million yuan, while central laboratory revenue declined 10 percent as the company continued transitioning Volume away from that channel.

Pharma Services Weakness Weighs on Overall Results

Revenue from pharma research and development services, which involves testing performed on behalf of pharmaceutical company customers, declined 31.8 percent year over year to 30.8 million yuan, reflecting decreased testing volume for these customers. This decline contributed to gross Margin compression in that channel to 47.2 percent from 56.8 percent a year earlier, though overall company gross margin held relatively steady at 72.6 percent.

Net loss widened to 18.4 million yuan from 9.7 million yuan in the prior year period, driven partly by increased general and administrative expenses tied to higher allowance for Credit losses on accounts receivable, alongside continued Investment in selling and Marketing to support the in-hospital business expansion. Research and development expenses declined 37.3 percent, reflecting what the company described as a temporary reduction across different research phases.

Regulatory Progress Could Support Future Growth

Several of the company's diagnostic products advanced through regulatory review during the quarter, including the OncoScreen BCMatch Tissue Kit entering the Priority Review Channel and the CanCatch Custom Kit entering the Special Review Procedure for Innovative Medical Devices, both under China's National Medical Products Administration. New registration certificates expected in coming quarters could support renewed Top Line growth if commercialization proceeds as management anticipates.

However, continued softness in pharma services revenue and central laboratory volume could persist if the transition toward in-hospital business takes longer than expected to offset these declines. The company's total partner hospital count held steady at 94, suggesting near term revenue growth may depend more on deepening existing hospital relationships and new product approvals than on rapid expansion of its hospital network.

Where Things Stand

Burning Rock Biotech's second quarter results reflect a business in transition, with sequential revenue recovery in its core in-hospital channel offset by continued weakness in pharma services and a widening net loss. Whether the anticipated wave of new regulatory approvals translates into sustainable top line growth may depend on the pace of commercialization and the company's ability to stabilize its pharma services business. Management's confidence in long term growth appears tied closely to these pending regulatory milestones rather than near term financial performance alone.